Sanofi Japan Looks Past Plavix Hit To New Launches
This article was originally published in PharmAsia News
Sanofi is facing a self-described “transitional period” in Japan and a couple of years of sales contraction as major products are opened up to generics. But the plan is to conduct more than 20 launches, including several biologics and line extensions, in the next four years, its new country president says.
You may also be interested in...
Non-Hygiene Personal Care ‘Essential’ In California … For Now; COVID-19 Event Impacts; Cosmetics News In Brief
Santa Monica, CA-based law firm Conkle, Kremer and Engle warns that while all personal-care product businesses appear to be designated “essential” in the Golden State under its statewide “stay at home” order, officials could decide that the policy does not apply to manufacturers of non-hygiene products. More cosmetics news in brief.
Pink Sheet Podcast: US FDA’s Chloroquine EUA And Coronavirus Treatment Accelerator, Novartis Receives No Penalty For Zolgensma Problems
Pink Sheet reporters and editors discuss the effects of the chloroquine emergency use authorization, FDA efforts to speed coronavirus treatment development, and the agency decision against penalizing Novartis over Zolgensma’s data integrity problems.
In this edition of the Device Week podcast, Medtech Insight managing editor Marion Webb discusses LifeSignals’ plans for a vital-sign monitoring patch that could help remotely monitor patients during the pandemic. Deputy editor Reed Miller highlights some important device trials presented at the American College of Cardiology online conference.